At present, the predictive markers of ICIs in melanoma treatment include the expression level of PD-L1 in tumor cells, the tumor mutation burden (TMB), the presence of tumor infiltrating lymphocytes (TIL), the presence of insertion and deletion (indel) mutations, the number of POLE mutations, specific gut microbiota, etc. [19]. This evidence concerns the gene POLE and melanoma.